Genomic Analysis of Benign Prostatic Hyperplasia

Benign prostatic hyperplasia (BPH) entails growth in the central regions of the prostate gland and is common among older men. BPH obstructs urinary outflow, resulting in voiding symptoms for which current treatments that target prostate physiology are only partially effective. A better understanding of BPH may suggest new treatment strategies that target its pathophysiology. The overall goal of the study is to apply next-generation sequencing-based approaches to investigate BPH, to discover new insight into BPH disease processes and new targets for precision therapy, and to determine whether the hyperplasia reflects underlying clonal expansions of prostatic cells.]]> Data were generated by RNAseq and DNAseq analysis of prostatic tissue specimens. All tissue specimens were acquired with IRB approval and patient informed consent, from radical prostatectomies for the diagnosis of prostate cancer that had concurrent BPH. Patients on 5-alpha-reductase inhibitors or alpha-adrenoceptor blocking agents (for treatment of BPH) were excluded from the study. Altogether, the study included prostatic tissue specimens from 40 subjects for bulk tissue RNAseq, 5 subjects for laser capture microdissection (LCM) RNAseq, 1 subject for single-cell RNAseq, and 18 subjects for whole-exome sequencing (WES). The study also includes 6 RNAseq samples from cell line experiments.]]>